Wockhardt Ltd

₹ 1,606 -1.89%

08 May - close price

wockhardt.com BSE: 532300 NSE: WOCKPHARMA

About

Wockhardt is a global pharmaceutical and biotechnology organization engaged in manufacturing finished dosage formulations, injectables, biopharmaceuticals, orals and topicals (creams and ointments). ^[1]

Key Points

Market Position
The company is amongst the top 3 Indian generic companies in the UK and the 6th largest generic supplier in the retail and hospital channels in Ireland. It is the No. 1 Methycobalamin brand in India. ^[1]

Website BSE NSE

Market Cap ₹ 26,104 Cr.
Current Price ₹ 1,606
High / Low ₹ 1,870 / 1,087
Stock P/E 89.4
Book Value ₹ 190
Dividend Yield 0.00 %
ROCE 9.74 %
ROE 9.99 %
Face Value ₹ 5.00

Add ratio to table

Edit ratios

Pros

Company is expected to give good quarter

Cons

Stock is trading at 8.46 times its book value
Company has a low return on equity of -1.83% over last 3 years.
Company has high debtors of 178 days.
Promoter holding has decreased over last 3 years: -10.2%
Working capital days have increased from -17.5 days to 178 days

* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.

Peer comparison

Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals

Part of BSE 500 BSE Healthcare Nifty 500 Nifty Pharma Nifty500 Shariah Nifty Smallcap 100 Nifty High Beta 50 BSE SmallCap Select Index BSE 250 SmallCap Index BSE 400 MidSmallCap Index Nifty MidSmallcap 400 Nifty Smallcap 50 Nifty Smallcap 250 Nifty 500 Multicap 50:25:25 Nifty Total Market Nifty MidSmall Healthcare Nifty500 Multicap India Manufacturing 50:30:20 Nifty500 Equal Weight Nifty500 LargeMidSmall Equal-Cap Weighted BSE 1000 Nifty500 Healthcare

Edit Columns

Loading peers table ...

Detailed Comparison with:

Quarterly Results

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	291	251	260	288	355	352	370	325	355	413	380	430	516
	321	256	270	263	401	272	321	263	249	282	267	317	355
Operating Profit	-30	-5	-10	25	-46	80	49	62	106	131	113	113	161
OPM %	-10%	-2%	-4%	9%	-13%	23%	13%	19%	30%	32%	30%	26%	31%
	-156	-8	6	5	24	27	11	6	14	25	30	17	90
Interest	58	58	59	61	59	58	53	48	40	41	44	50	41
Depreciation	45	44	44	43	45	43	43	42	40	46	45	52	43
Profit before tax	-289	-115	-107	-74	-126	6	-36	-22	40	69	54	28	167
Tax %	3%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%	0%
	-299	-115	-107	-74	-126	6	-36	-22	40	69	54	28	167
EPS in Rs	-20.75	-7.98	-7.43	-5.14	-8.21	0.39	-2.35	-1.35	2.46	4.25	3.32	1.72	10.28
Raw PDF

Profit & Loss

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	1,887	2,217	2,298	2,477	1,557	890	987	1,372	1,072	1,154	1,402	1,739
	1,879	2,091	2,153	2,154	1,619	1,023	1,125	1,150	1,002	1,190	1,102	1,222
Operating Profit	7	126	145	323	-62	-133	-138	222	70	-36	300	517
OPM %	0%	6%	6%	13%	-4%	-15%	-14%	16%	7%	-3%	21%	30%
	465	62	248	57	126	138	884	38	-168	27	55	162
Interest	19	108	169	170	171	220	200	273	229	237	199	176
Depreciation	103	99	106	106	120	173	184	171	186	176	168	186
Profit before tax	350	-20	119	104	-227	-389	362	-184	-513	-422	-12	317
Tax %	5%	-143%	-15%	34%	-64%	-41%	-64%	-24%	-9%	0%	0%	0%
	332	8	137	69	-82	-231	593	-140	-466	-422	-12	317
EPS in Rs	23.19	0.58	9.54	4.77	-5.69	-16.05	41.18	-9.72	-32.34	-27.51	-0.74	19.51
Dividend Payout %	66%	0%	81%	0%	0%	0%	0%	0%	0%	0%	0%	0%

Compounded Sales Growth
10 Years:	-2%
5 Years:	12%
3 Years:	18%
TTM:	24%

Compounded Profit Growth
10 Years:	43%
5 Years:	-17%
3 Years:	48%
TTM:	2533%

Stock Price CAGR
10 Years:	6%
5 Years:	24%
3 Years:	111%
1 Year:	31%

Return on Equity
10 Years:	0%
5 Years:	-5%
3 Years:	-2%
Last Year:	10%

Balance Sheet

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	55	55	55	55	55	55	55	72	72	77	81	81
Reserves	1,016	1,113	1,164	1,239	1,171	939	1,551	2,140	1,681	1,719	2,682	3,003
	1,138	1,984	2,120	1,773	1,885	2,370	2,078	2,024	2,013	2,136	1,796	1,964
	1,939	1,431	1,230	1,318	1,426	1,395	1,211	1,562	966	936	849	887
Total Liabilities	4,149	4,584	4,569	4,386	4,538	4,760	4,895	5,798	4,732	4,868	5,408	5,935
	1,005	1,402	1,465	1,423	1,614	2,044	1,684	1,828	1,625	1,449	1,276	2,628
CWIP	792	664	665	653	381	305	716	825	823	833	1,260	121
Investments	297	297	297	297	297	297	297	297	297	297	719	709
	2,054	2,221	2,142	2,013	2,245	2,113	2,198	2,848	1,987	2,289	2,153	2,477
Total Assets	4,149	4,584	4,569	4,386	4,538	4,760	4,895	5,798	4,732	4,868	5,408	5,935

Cash Flows

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	-53	-363	-235	119	58	222	-563	-93	71	188	-14	241
	203	-1,015	369	451	120	-16	1,014	-244	-3	-75	-900	-193
	425	764	-133	-524	-69	-274	-480	430	-236	346	486	-7
Net Cash Flow	575	-614	1	46	109	-69	-29	93	-168	459	-428	41
Free Cash Flow	-349	-644	-396	75	34	199	-1,088	-346	63	100	-508	-26
CFO/OP	500%	-285%	-145%	40%	-134%	-167%	328%	-6%	109%	-522%	-14%	47%

Ratios

Standalone Figures in Rs. Crores / View Consolidated

	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor Days	41	45	54	118	236	385	353	344	188	179	159	178
Inventory Days	240	216	206	141	195	367	305	297	330	254	357	469
Days Payable	158	134	133	167	325	611	355	446	507	459	398	442
Cash Conversion Cycle	123	126	127	92	105	141	303	194	11	-26	117	204
Working Capital Days	-223	-18	-73	-55	-52	-351	-334	-231	-404	-223	-7	178
ROCE %	20%	3%	9%	9%	-2%	-8%	-8%	2%	-1%	-4%	4%	10%

Insights

In beta

Mar 2015

Mar 2016

Mar 2017

Mar 2018

Mar 2020

Mar 2021

Mar 2022

Mar 2023

Mar 2024

Mar 2025

Emerging Markets Sales Contribution
%

xx	x	x	xx	xx	xx	xx	xx	xx	xx
xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx	xx.xx
xx	xx	xx	xx	xx	xx	xx	xx	xx	xx
x	x	x	x		x	x	x	x	x
x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx	x,xxx
					xx	xx	xx		xx
		xxx			xxx	xxx	xxx
					xx	xx	xx		xx
							xx,xxx	xx,xxx	xxx,xxx
									xx
									xxx
									xx
				x.xx	x.xx	x.xx		x.xx

Please log in to see hidden values.

India Sales Contribution
%

Manufacturing Facilities Overall
Count

Number of Programs granted QIDP status by US FDA
Count

Total Employees
Count

Scientists within Drug Discovery Team with PhDs
Count

Total Scientists employed
Count

UK Sales Contribution
%

Patients treated with EMROK/EMROK O (Cumulative)
Patients

Compassionate use lives saved (ZAYNICH)
Lives

Drug Discovery Team
Total Personnel

Market Share of EMROK in target segment
%

R&D Expenditure (Percentage of Turnover)
%

Extracted by Screener AI

Shareholding Pattern

Numbers in percentages

2 Recently

	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026
	58.40%	55.14%	54.93%	51.60%	51.99%	51.99%	49.09%	49.09%	49.09%	49.09%	49.09%	49.09%
	2.60%	3.03%	4.18%	5.49%	5.94%	6.70%	6.54%	6.82%	7.29%	7.10%	7.00%	7.09%
	0.18%	0.21%	0.30%	4.82%	4.45%	5.08%	9.82%	10.58%	11.00%	11.00%	10.55%	10.96%
	0.00%	0.00%	0.00%	0.01%	0.01%	0.02%	0.02%	0.02%	0.02%	0.02%	0.02%	0.04%
	38.83%	41.62%	40.59%	38.06%	37.62%	36.21%	34.54%	33.50%	32.60%	32.79%	33.36%	32.84%
No. of Shareholders	1,78,915	1,72,989	1,61,813	1,46,138	1,40,391	1,38,142	1,42,710	1,41,799	1,46,918	1,37,946	1,42,274	1,39,016

	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
	74.25%	74.11%	74.07%	72.13%	72.12%	67.13%	59.31%	51.60%	49.09%	49.09%
	4.55%	5.45%	4.74%	4.85%	3.10%	2.89%	2.78%	5.49%	6.82%	7.09%
	2.71%	4.99%	2.55%	0.24%	0.09%	0.09%	0.22%	4.82%	10.58%	10.96%
	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.01%	0.02%	0.04%
	18.49%	15.45%	18.64%	22.78%	24.69%	29.89%	37.70%	38.06%	33.50%	32.84%
No. of Shareholders	1,24,403	99,736	1,14,338	1,17,324	1,25,488	1,72,460	1,82,493	1,46,138	1,41,799	1,39,016

* The classifications might have changed from Sep'2022 onwards. The new XBRL format added more details from Sep'22 onwards.

Classifications such as banks and foreign portfolio investors were not available earlier. The sudden changes in FII or DII can be because of these changes.

Click on the line-items to see the names of individual entities.

Documents

Announcements

All

Annual reports

Right Issue

Credit ratings

Concalls

Jun 2025
Transcript PPT
Jun 2025

Transcript

AI Summary
PPT
Feb 2025

Transcript

AI Summary
PPT
Oct 2024

Transcript

AI Summary
PPT
Feb 2024

Transcript

AI Summary
PPT
Feb 2023
Transcript PPT
Mar 2022

Transcript

AI Summary
PPT